Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.43 |
| ▸ | RAMP3 | O60896 | 7/20 | 0.43 |
| ▸ | CALCR | P30988 | 7/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31655138 | 0.98 | NMUR2 (0.43) | NMUR2NMUR1CXCR4KEAP1RAMP3 | |
| SCHEMBL31655163 | 0.97 | CXCR4 (0.47) | NMUR2NMUR1CXCR4KEAP1RAMP3 | |
| SCHEMBL30006262 | 0.96 | NMUR2 (0.46) | NMUR2NMUR1CXCR4RAMP3CALCR | |
| SCHEMBL28356821 | 0.95 | CXCR4 (0.47) | NMUR2NMUR1CXCR4OPRM1OPRD1 | |
| SCHEMBL30275450 | 0.91 | CXCR4 (0.46) | NMUR2NMUR1CXCR4KEAP1OPRD1 | |
| SCHEMBL29864852 | 0.90 | OPRM1 (0.51) | NMUR2NMUR1CXCR4RAMP3CALCR | |
| SCHEMBL29864927 | 0.90 | OPRM1 (0.51) | NMUR2NMUR1CXCR4RAMP3CALCR | |
| SCHEMBL29864866 | 0.90 | OPRM1 (0.51) | NMUR2NMUR1CXCR4RAMP3CALCR | |
| SCHEMBL29374733 | 0.90 | CXCR4 (0.45) | NMUR2NMUR1CXCR4KEAP1 | |
| SCHEMBL29429189 | 0.90 | NMUR2 (0.46) | NMUR2NMUR1CXCR4KEAP1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222121-A1 | MULTIVALENT SMAC/DIABLO PROTEIN PEPTIDOMIMETIC COVALENTLY LINKED TO A TUMOR-HOMING PEPTIDE FOR TREATING CANCERS | BIOXEL INC. (US) | 2025-07-10 | — | — | US | claimed |
| US-20250213706-A1 | MULTIFUNCTIONAL PROTEOLYSIS-TARGETING CHIMERA CONJUGATES | BIOXEL INC. (US) | 2025-07-03 | — | — | US | claimed |
| US-20250222121-A1 | MULTIVALENT SMAC/DIABLO PROTEIN PEPTIDOMIMETIC COVALENTLY LINKED TO A TUMOR-HOMING PEPTIDE FOR TREATING CANCERS | BIOXEL INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-20250213706-A1 | MULTIFUNCTIONAL PROTEOLYSIS-TARGETING CHIMERA CONJUGATES | BIOXEL INC. (US) | 2025-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213706-A1 | MULTIFUNCTIONAL PROTEOLYSIS-TARGETING CHIMERA CONJUGATES | PSMA6, PSMA1, CUL2 | NMUR2 4437/4885NMUR1 4279/4885CXCR4 2836/4885 |
| US-20250222121-A1 | MULTIVALENT SMAC/DIABLO PROTEIN PEPTIDOMIMETIC COVALENTLY LINKED TO A TUMOR-HOMING PEPTIDE FOR TREATING CANCERS | BIRC2, BIRC3, BIRC7 | NMUR2 3983/4885NMUR1 3705/4885CXCR4 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.